FoxO3a gene is a target of deletion in mouse lung adenocarcinoma

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 837-843

  Herzog, Christopher R ^a   Blake Jr , Daniel C ^a   Mikse, Oliver R ^a   Grigoryeva, Lubov S ^a   Gundermann, Erica L ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Carcinogenesis; FoxO3a; Lung adenocarcinoma; Tumor suppressor

Indexed keywords

TRANSCRIPTION FACTOR FKHRL1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 10; CONTROLLED STUDY; GENE DELETION; GENE IDENTIFICATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENOCARCINOMA; AFLATOXIN B1; ANIMALS; CARCINOGENS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE DELETION; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MICE; NITROSAMINES; POLYMERASE CHAIN REACTION; SMOKING; URETHANE;

EID: 70350379161     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000507     Document Type: Article

References (51)

1. American Cancer Society: Cancer Facts and Figures 2007. American Cancer Society, Atlanta, 2008.
2. International Agency for Research on Cancer (IARC): Monographs on the Evaluations of Carcinogenic Risks to Humans. IARC, Lyon, 2002.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Wistuba II, Mao L and Gazdar AF: Smoking molecular damage in bronchial epithelium. Oncogene 21: 7298-7306, 2002.
5. Wong MP, Lam WK, Wang E, Chiu SW, Lam CL and Chung LP: Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 62: 4464-4468, 2002.
6. Sy SM, Wong N, Mok TS, Tsao MS, Lee TW, Tse G, Blackhall FH, Johnson PJ and Yim AP: Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. Lung Cancer 41: 91-99, 2003.
7. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J and Sidransky D: Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61: 1309-1313, 2001.
8. Powell CA, Bueno R, Borczuk AC, Caracta CF, Richards WG, Sugarbaker DJ and Brody JS: Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers: Lung Cancer 39: 23-29, 2003.
9. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ and Sidransky D: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001.
10. Sekido Y, Fong KM and Minna JD: Molecular genetics of lung cancer. Ann Rev Med 54: 73-87, 2003.
11. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
12. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladany M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: 57-61, 2005.
13. Dutu T, Michiels S, Fouret P, Penault-Llorca F, Validire P, Benhamou S, Taranchon E, Morat L, Grunenwald D, Le Chevalier T, Sabatier L and Soria JC: Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Annul Oncol 16: 1906-1914, 2005.
14. Sun S, Schiller JH and Gadzar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer 7: 778-790, 2007.
15. Herzog CR, Lubet RA and You M: Genetic alterations in mouse lung tumors: implications for cancer prevention. J Cell Biochem 28/29: 49-63, 1997.
16. You M, Candrian U, Maronpot RR, Stoner GD and Anderson M: Activation of the K-ras gene in spontaneously occurring and chemically-induced strain A mouse lung tumors. Proc Natl Acad Sci USA 86: 3070-3074, 1989.
17. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD and Gazdar AF: Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21: 308-319, 1998.
18. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, Langreck H, Gellert K, Reichel M, Just K, du Manoir S, Cremer T, Dietel M and Ried T: Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 57: 2331-2335, 1997.
19. Herzog CR, Bodon N, Pittman B, You M, Anderson MW, Maronpot RR, Massey TE and Devereux TR: Carcinogen-specific targeting of chromosome 12 for loss of heterozygosity in mouse lung adenocarcinomas: Implications for chromosome instability induction and tumor progression. Oncogene 23: 3033-3039, 2004.
20. Herzog CR, Desai D and Amin S: Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochem Biophys Res Com 341: 856-863, 2006.
21. You M, Wang D, Liu P, Vikis H, James M, Lu Y, Wang Y, Wang M, Chen Q, et al: Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 15: 2666-2674, 2009.
22. Hecht SS, Chen CB, Hirota N, Ornaf RM, Tso TC and Hoffmann D: Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J Natl Cancer Inst 60: 819-824, 1978.
23. Dahl GA, Miller JA and Miller EC: Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. Cancer Res 38: 3793-3804, 1978.
24. Massey TE, Smith GB and Tam AS: Mechanisms of aflatoxin B1 lung tumorigenesis. Exp Lung Res 26: 673-683, 2000.
25. Sargent LM, Senft JR, Lowry DT, Jefferson AM, Tyson FL, Malkinson AM, Coleman AE and Reynolds SH: Specific chromosomal aberrations in mouse lung adenocarcinoma cell lines detected by spectral karyotyping: a comparison with human lung adenocarcinoma. Cancer Res 62: 1152-1157, 2002.
26. Hinds PW and Weinberg RA: Tumor suppressor genes. Curr Opin Genet Dev 4: 135-141,1994.
27. Hayashi Y, Raimondi SC, Look AT, Behm FG, Kitchingman GR, Pui CH, Rivera GK and Williams DL: Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 76: 1626-1630, 1990.
28. Chuaqui R, Silva M and Emmert-Buck M: Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma. Gynecol Oncol 80: 364-371, 2001.
29. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643-649, 1998.
30. Loeb LA: Cancer cells exhibit a mutator phenotype. Adv Cancer Res 72: 25-56, 1998.
31. Gisselsson D: Chromosome instability in cancer: how, when, and why? Adv Cancer Res 87: 1-29, 2003.
32. Morelli C, Karayianni E, Magnanini C, Mungall AJ, Thorland E, Negrini M, Smith DI and Barbanti-Brodano G: Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 21: 7266-7276, 2002.
33. Glover TW, Arl MF, Casper AM and Durkin SG: Mechanisms of common fragile site instability. Hum Mol Genet 2: 197-205, 2005.
34. Arlt MF, Durkin SG, Ragland RL and Glover TW: Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5: 1126-1135, 2006.
35. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH and DePinho RA: FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323, 2007.
36. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al: LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810, 2007.
37. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005.
38. Dansen TB and Burgering BM: Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol 18: 421-429, 2008.
39. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K and Motoyama N: FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem 277: 26729-26732, 2002.
40. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH and Burgering BM: Forkhead transcription factor FoxO3a protects quiescent cells from oxidative stress. Nature 419: 316-321, 2002.
41. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW and Greenberg ME: DNA repair pathway stimulated by the forkhead transcription factor FoxO3a through the Gadd45 protein. Science 296: 530-534, 2002.
42. Bakker WJ, Harris IS and Mak TW: FoxO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 28: 941-953, 2007.
43. Blake Jr DC, Mikse OR, Freeman WM and Herzog CR: FOXO3a stimulates a pro-apoptotic transcriptional program in response to human lung carcinogen nicotine-derived nitro-saminoketone. Lung Cancer (In press).
44. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
45. Nakamura N, Ramaswany F, Vasquez S, Signoretti M, Loda M and Sellers WR: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982, 2000.
46. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R and Hung MC: IκB kinase promotes tumorigenesis through inhibition of forkhead FoxO3a. Cell 117: 225-237, 2004.
47. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
48. Burgering BM and Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995.
49. Engelman JA and Jänne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899, 2008.
50. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
51. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003.